Literature DB >> 32166460

Genomic Subtyping in Bladder Cancer.

Tuomas Jalanko1,2, Joep J de Jong3, Ewan A Gibb4, Roland Seiler5, Peter C Black6.   

Abstract

PURPOSE OF REVIEW: Molecular characterization of cancer allows us to understand oncogenesis and clinical prognosis as well as facilitates development of biomarkers and treatment. Our aim was to review the current literature on genomic characterization of bladder cancer, and how far we are in implementing genomics into clinical practice. RECENT
FINDINGS: Bladder cancers are molecularly diverse tumors with a high mutational rate. On molecular level, bladder cancer can be categorized into at least six subtypes called luminal-papillary, luminal-unstable, luminal non-specified, basal-squamous, neuroendocrine-like, and stroma-rich. These subtypes have characteristic genomic and transcriptomic profiles and appear to have different prognoses. Several molecular subtypes have been identified in bladder cancer. Prospective trials are underway to validate the applicability of genomic subtypes for clinical decision making. Further integrative analyses of genomic alterations, gene expression, epigenetics, and proteomics need to be performed before genomic subtyping can be attained in clinical practice.

Entities:  

Keywords:  Bladder cancer; Genomic analysis; Immunotherapy; Molecular subtyping; Mutations; Neoadjuvant chemotherapy

Year:  2020        PMID: 32166460     DOI: 10.1007/s11934-020-0960-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  69 in total

1.  ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers.

Authors:  Woonyoung Choi; David J McConkey
Journal:  Eur Urol       Date:  2018-10-23       Impact factor: 20.096

2.  Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Authors:  Sumanta K Pal; Jonathan E Rosenberg; Jean H Hoffman-Censits; Raanan Berger; David I Quinn; Matthew D Galsky; Juergen Wolf; Christian Dittrich; Bhumsuk Keam; Jean-Pierre Delord; Jan H M Schellens; Gwenaelle Gravis; Jacques Medioni; Pablo Maroto; Virote Sriuranpong; Chaiyut Charoentum; Howard A Burris; Viktor Grünwald; Daniel Petrylak; Ulka Vaishampayan; Eliahu Gez; Ugo De Giorgi; Jae-Lyun Lee; Jens Voortman; Sumati Gupta; Sunil Sharma; Amir Mortazavi; David J Vaughn; Randi Isaacs; Katie Parker; Xueying Chen; Kun Yu; Dale Porter; Diana Graus Porta; Dean F Bajorin
Journal:  Cancer Discov       Date:  2018-05-30       Impact factor: 39.397

3.  Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Authors:  Jakob Hedegaard; Philippe Lamy; Iver Nordentoft; Ferran Algaba; Søren Høyer; Benedicte Parm Ulhøi; Søren Vang; Thomas Reinert; Gregers G Hermann; Karin Mogensen; Mathilde Borg Houlberg Thomsen; Morten Muhlig Nielsen; Mirari Marquez; Ulrika Segersten; Mattias Aine; Mattias Höglund; Karin Birkenkamp-Demtröder; Niels Fristrup; Michael Borre; Arndt Hartmann; Robert Stöhr; Sven Wach; Bastian Keck; Anna Katharina Seitz; Roman Nawroth; Tobias Maurer; Cane Tulic; Tatjana Simic; Kerstin Junker; Marcus Horstmann; Niels Harving; Astrid Christine Petersen; M Luz Calle; Ewout W Steyerberg; Willemien Beukers; Kim E M van Kessel; Jørgen Bjerggaard Jensen; Jakob Skou Pedersen; Per-Uno Malmström; Núria Malats; Francisco X Real; Ellen C Zwarthoff; Torben Falck Ørntoft; Lars Dyrskjøt
Journal:  Cancer Cell       Date:  2016-06-16       Impact factor: 31.743

4.  FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.

Authors:  Joshua I Warrick; Matthew Kaag; Jay D Raman; Wilson Chan; Truc Tran; Sudhir Kunchala; Lauren Shuman; David DeGraff; Guoli Chen
Journal:  Virchows Arch       Date:  2017-07-18       Impact factor: 4.064

5.  First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Leora Horn; Aaron S Mansfield; Aleksandra Szczęsna; Libor Havel; Maciej Krzakowski; Maximilian J Hochmair; Florian Huemer; György Losonczy; Melissa L Johnson; Makoto Nishio; Martin Reck; Tony Mok; Sivuonthanh Lam; David S Shames; Juan Liu; Beiying Ding; Ariel Lopez-Chavez; Fairooz Kabbinavar; Wei Lin; Alan Sandler; Stephen V Liu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

6.  Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21.

Authors:  T Waldman; C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

7.  Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.

Authors:  Sonata Jarmalaite; Feliksas Jankevicius; Kristina Kurgonaite; Kestutis Suziedelis; Pertti Mutanen; Kirsti Husgafvel-Pursiainen
Journal:  Oncology       Date:  2008-09-29       Impact factor: 2.935

8.  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

Authors:  J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal
Journal:  Eur Urol       Date:  2016-06-30       Impact factor: 20.096

9.  An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.

Authors:  Evanguelos Xylinas; Melanie R Hassler; Dazhong Zhuang; Martin Krzywinski; Zeynep Erdem; Brian D Robinson; Olivier Elemento; Thomas Clozel; Shahrokh F Shariat
Journal:  Biomolecules       Date:  2016-09-02

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

View more
  2 in total

1.  Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.

Authors:  Xin Huang; Hao-Fei Wang; Shuang Huang
Journal:  Front Genet       Date:  2022-08-17       Impact factor: 4.772

2.  RalGPS2 Interacts with Akt and PDK1 Promoting Tunneling Nanotubes Formation in Bladder Cancer and Kidney Cells Microenvironment.

Authors:  Alessia D'Aloia; Edoardo Arrigoni; Barbara Costa; Giovanna Berruti; Enzo Martegani; Elena Sacco; Michela Ceriani
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.